Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Flachenecker

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Journal of Neurology|March 21, 2009
National MS registriesPeter Flachenecker, Kristin Stuke
Drugs|July 31, 2003
Early intervention in multiple sclerosis : better outcomes for patients and society?Peter Flachenecker, Peter Rieckmann
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2008
Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessmentPeter Flachenecker, Heike Meissner
Case Reports in Neurology|August 25, 2018
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video RecordingsPeter Flachenecker, Francesco Saccà, Carlos Vila
European Neurology|February 15, 2014
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityPeter Flachenecker, Thomas Henze, Uwe K Zettl
European Neurology|June 20, 2014
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practicePeter Flachenecker, Thomas Henze, Uwe K Zettl
European Neurology|October 27, 2017
Neuropsychological Training of Attention Improves MS-Related Fatigue: Results of a Randomized, Placebo-Controlled, Double-Blind Pilot StudyPeter Flachenecker, Heike Meissner, Rebecca Frey, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 3, 2013
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)Uwe K Zettl, Thomas Henze, Ute Essner, et al.
Journal of Neurology|August 27, 2002
sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot studyPeter Flachenecker, Stefan Jung, Peter Rieckmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2017
New insights into the burden and costs of multiple sclerosis in Europe: Results for GermanyPeter Flachenecker, Gisela Kobelt, Jenny Berg, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Journal of Neurology|March 21, 2009
National MS registriesPeter Flachenecker, Kristin Stuke
Drugs|July 31, 2003
Early intervention in multiple sclerosis : better outcomes for patients and society?Peter Flachenecker, Peter Rieckmann
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2008
Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessmentPeter Flachenecker, Heike Meissner
Case Reports in Neurology|August 25, 2018
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video RecordingsPeter Flachenecker, Francesco Saccà, Carlos Vila
European Neurology|February 15, 2014
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticityPeter Flachenecker, Thomas Henze, Uwe K Zettl
European Neurology|June 20, 2014
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practicePeter Flachenecker, Thomas Henze, Uwe K Zettl
European Neurology|October 27, 2017
Neuropsychological Training of Attention Improves MS-Related Fatigue: Results of a Randomized, Placebo-Controlled, Double-Blind Pilot StudyPeter Flachenecker, Heike Meissner, Rebecca Frey, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 3, 2013
Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I)Uwe K Zettl, Thomas Henze, Ute Essner, et al.
Journal of Neurology|August 27, 2002
sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot studyPeter Flachenecker, Stefan Jung, Peter Rieckmann, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 24, 2017
New insights into the burden and costs of multiple sclerosis in Europe: Results for GermanyPeter Flachenecker, Gisela Kobelt, Jenny Berg, et al.
Pageof 7